

1 **Upper respiratory tract SARS-CoV-2 RNA loads in symptomatic and**
2 **asymptomatic children and adults**

3 Rosa Costa¹, Felipe Bueno¹, Eliseo Albert¹, Ignacio Torres¹, Silvia Carbonell-
4 Sahuquillo², Ana Barrés-Fernández², David Sánchez¹, Carmelo Padrón¹, Javier
5 Colomina¹, María Isabel Lázaro Carreño^{2,3}, José Rafael Bretón-Martínez^{2,3}, Cecilia
6 Martínez-Costa^{2,3} and David Navarro^{1,4*}

7 ¹*Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute,*
8 *Valencia, Spain.*

9 ²*Pediatric Department, Hospital Clínico Universitario, Valencia, Spain.*

10 ³*Department of Pediatrics, University of Valencia, Valencia, Spain*

11 ⁴*Department of Microbiology, School of Medicine, University of Valencia, Valencia,*
12 *Spain.*

13

14 ***Correspondence:** David Navarro, Microbiology Service, Hospital Clínico
15 Universitario, Instituto de Investigación INCLIVA, Valencia, and Department of
16 Microbiology, University of Valencia, Valencia, Spain. Av. Blasco Ibáñez 17, 46010
17 Valencia, Spain. Phone: 34(96)1973500; Fax: 34(96)3864173; E-mail:
18 david.navarro@uv.es.

19 **Key words:** SARS-CoV-2 RNA, viral load, children, adults, COVID-19.

20 **Running title:** SARS-CoV-2 RNA load in nasopharyngeal specimens from children
21 and adults.

22

23

24

25

26

27 **ABSTRACT**

28 **Objectives:** There is limited information comparing SARS-CoV-2 RNA load in the
29 upper respiratory tract (URT) between children and adults, either presenting with
30 COVID-19 or asymptomatic. Here we conducted a retrospective, single center study
31 involving a large cohort of SARS-CoV-2 infected individuals to address this issue.

32 **Patients and Methods:** A total of 1,184 consecutive subjects (256 children and 928
33 adults) testing positive for SARS-COV-2 RNA in nasopharyngeal exudates (NP) were
34 included, of whom 424 (121 children and 303 adults) had COVID-19 not requiring
35 hospitalization and 760 (135 children and 625 adults) were asymptomatic close contacts
36 of COVID-19 patients. SARS-CoV-2 RNA testing was carried out using the TaqPath
37 COVID-19 Combo Kit (Thermo Fisher Scientific, MS, USA). The AMPLIRUN®
38 TOTAL SARS-CoV-2 RNA Control (Vircell SA, Granada, Spain) was used for
39 estimating SARS-CoV-2 RNA loads (in copies/mL).

40 **Results:** Median SARS-COV-2 RNA loads were comparable between adults and
41 children with COVID-19 (7.14 log₁₀ copies/ml vs. 6.98 log₁₀ copies/ml; $P=0.094$).
42 Median SARS-CoV-2 RNA load in asymptomatic children and adults was similar (6.20
43 log₁₀ copies/ml vs. 6.48 log₁₀ copies/ml; $P=0.97$). Children with COVID-19 symptoms
44 displayed SARS-CoV-2 RNA loads comparable to their asymptomatic counterparts
45 ($P=0.61$). Meanwhile in adults, median SARS-CoV-2 RNA load was significantly
46 higher in symptomatic than in asymptomatic subjects ($P=<0.001$), yet comparable
47 ($P=0.61$) when the analysis excluded patients sampled within 48 h after symptoms
48 onset.

49 **Conclusions:** The data suggest that children may be drivers of SARS-CoV-2
50 transmission in the general population at the same level as adults.

51 **Key words:** SARS-CoV-2 RNA, upper respiratory tract, viral load, children, adults,
52 COVID-19.

53 **INTRODUCTION**

54 An increasing body of evidence suggests that children are less susceptible to SARS-
55 CoV-2 infection and tend to develop milder forms of COVID-19 than adults [1].
56 Nevertheless, whether children, either symptomatic or asymptomatic, play a major role
57 in community transmission of SARS-CoV-2 compared to adults remains unclear [1].
58 There is a consistent direct correlation between magnitude of SARS-CoV-2 RNA load
59 in the upper respiratory tract (URT) and probability of recovering live virus in cell
60 culture, in both adults and children [2-5]; hence, viral load in URT may be used as a
61 proxy for contagiousness. Supporting this assumption, transmission risk was recently
62 shown to be strongly associated with initial SARS-CoV-2 RNA levels of index cases
63 [6]. There is scarce information on how SARS-CoV-2 RNA load in UTR compares
64 between children and adults [7-11], whether viral load in pediatric subjects differ across
65 ages [9,10], and whether dissimilarities in the dynamics of SARS-CoV-2 shedding in
66 URT exist between symptomatic and asymptomatic children [12-14]. Elucidation of
67 these questions is critically important for designing effective public health policies to
68 fight the pandemic. Here, to gain a further insight into these issues, we conducted a
69 retrospective, single center study involving a substantial cohort of SARS-CoV-2
70 infected children and adults, either asymptomatic or symptomatic, non-hospitalized
71 cases.

72 **METHODS**

73 **Patients and specimens**

74 A total of 1,184 consecutive subjects testing positive for SARS-COV-2 RNA in
75 nasopharyngeal exudates (NP) between June 2020 and January 2021 were included.
76 Participants were pediatric individuals (≤ 18 years; $n=256$; 21.6%), aged a median of 12
77 years (range, 0-18 years) or adults (>18 years; $n=928$; 78.3%), aged a median age of 37
78 years (range, 19-93 years). A total of 967 participants (154 children and 813 adults)
79 were sampled at primary health centers belonging to the Health Department Clínico-
80 Malvarrosa, Valencia (Spain), while 217 (102 children and 115 adults) were sampled at
81 the Emergency Department of Hospital Clínico Universitario of Valencia. A total of 424
82 subjects (children, $n=121$; adults, $n=303$) presented with symptoms compatible with
83 COVID-19, including one or more of the following: fever, dry cough, rhinorrhea,
84 dyspnea, myalgia, fatigue, anosmia, ageusia, odynophagia, diarrhea, conjunctivitis, and
85 cephalaea, none requiring hospitalization. A total of 760 participants (135 children and
86 625 adults) were asymptomatic close contacts of COVID-19 patients, as previously
87 defined [15]. NP specimen collection in the latter group was prescribed at the discretion
88 of either the physician in charge of the index case or local health authorities, and was
89 performed at a median of 7 days (range, 1-10 days) after diagnosis of the presumed
90 index case. Initial SARS-CoV-2 RNA loads were used throughout the current study for
91 comparison purposes. The current study was approved by the Research Ethics
92 Committee of Hospital Clínico Universitario INCLIVA (March 2020).

93 **SARS-CoV-2 RNA testing**

94 NPs were collected by trained nurses at sampling sites and were placed in 3 mL of
95 Universal Transport Medium (Becton Dickinson, Sparks, MD, USA). RT-PCRs were
96 carried out at the Microbiology Service of Hospital Clínico Universitario within 24 h of

97 specimen collection. The TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific,
98 MS, USA), which targets SARS-CoV-2 ORF1ab, N and S genes, was used following
99 RNA extraction carried out using the Applied Biosystems™ MagMAX™
100 Viral/Pathogen II Nucleic Acid Isolation Kits coupled with Thermo Scientific™
101 KingFisher Flex automated instrument. The AMPLIRUN® TOTAL SARS-CoV-2
102 RNA Control (Vircell SA, Granada, Spain) was used as the reference material for
103 estimating SARS-CoV-2 RNA load (in copies/mL, taking RT-PCR CTs for the N gene)
104 [16,17].

105 **RT-PCR β -glucuronidase RNA testing**

106 We amplified the β -glucuronidase (GUSB) housekeeping gene to assess specimen
107 cellularity in selected specimens following a previously published protocol [18]. In
108 brief, RNA was extracted from NP using the DSP virus Pathogen Minikit on the
109 QiaSymphony Robot instruments (Qiagen, Valencia, CA), reverse-transcribed to
110 complementary DNA and subsequently amplified by using the HEQC one-step kit
111 (Seqplexing, Valencia, Spain) in the LightCycler 480 Real-Time PCR System Version
112 II (Roche Diagnostics, Pleasanton).

113 **Statistical methods**

114 Differences between medians across groups were compared in a pairwise fashion using
115 the non-parametric Mann–Whitney U-test, given that SARS-COV-2 RNA loads were
116 non-normally distributed. Spearman’s rank test was used to test the association between
117 age and SARS-CoV-2 RNA load. Two-sided exact *P*-values were reported. A *P*-value
118 <0.05 was considered statistically significant. The analyses were performed using SPSS
119 version 20.0 (SPSS, Chicago, IL, USA).

120 **RESULTS**

121 **SARS-CoV-2 RNA load in pediatric and adult COVID-19 patients**

122 We first compared initial SARS-CoV-2 RNA load in NP from symptomatic pediatric
123 and adult patients. Specimen collection was carried out at a median of 2 days (range, 0-
124 10 days) and a median of 3 days (range, 0-10 days), respectively, after symptoms onset.
125 The data are shown in Fig. 1A. The range of estimated SARS-COV-2 RNA loads
126 appeared comparable between children and adults; nevertheless, a trend towards a lower
127 median viral RNA load was observed in children compared to adults (6.98 log₁₀
128 copies/ml and 7.14 log₁₀ copies/ml and), although the difference did not reach statistical
129 significance ($P=0.094$).

130 We next compared initial SARS-CoV-2 RNA load in children and adults by time of NP
131 sampling after symptoms onset. Since SARS-CoV-2 RNA load peaks within the first 48
132 h after COVID-19 clinical presentation [18], we split each patient group into two
133 subgroups (<3 days/≥3 days). As anticipated, SARS-CoV-2 RNA load was significantly
134 higher in NP specimens collected within 48 h after onset of symptoms than in those
135 obtained later on, in both children (median, 7.46 log₁₀ copies/ml vs. 5.17 log₁₀
136 copies/ml; $P<0.001$) and adults (7.81 log₁₀ copies/ml vs. 6.45 log₁₀ copies/ml;
137 $P=0.002$) (Fig. 2). Interestingly, SARS-CoV-2 RNA load measured within 48 h after
138 symptoms onset was comparable ($P=0.263$) between children and adults, whereas those
139 determined at later times (>48 h) were significantly lower in children ($P=0.002$).

140 Finally, we compared initial SARS-CoV-2 RNA loads across age groups conventionally
141 defined for children (infants, toddlers, preschoolers, school-aged, and adolescents) and
142 arbitrarily set for adults (18 to 65 years/>65 years). Pairwise comparison analyses are
143 shown in Fig. 1B. Overall, there were no between-group differences in either children or
144 adults ($P=>0.14$ for all pairwise comparisons). Moreover, as shown in Fig. 3A and 3B,

145 no correlation was found between SARS-CoV-2 RNA loads and patient age, either for
146 children (Rho, 0.008 $P=0.93$) or adults (Rho, 0.005; $P=0.92$).

147 **SARS-CoV-2 RNA load in asymptomatic children and adults**

148 A wide range of SARS-CoV-2 RNA loads were detected in asymptomatic children and
149 adults (Fig. 4A), likely reflecting the broad spectrum of NP collection times after
150 exposure to the presumed index case which, it should be noted, was not dissimilar
151 between children and adults. SARS-CoV-2 RNA loads in asymptomatic children
152 (median, 6.20 \log_{10} copies/ml) and adults (median, 6.48 \log_{10} copies/ml) were
153 comparable in magnitude ($P=0.97$). Likewise, no differences in SARS-CoV-2 RNA
154 loads were observed across pediatric ages or between adults aged ≤ 65 years or older
155 (Fig. 4B) and no correlation was found between age and SARS-CoV-2 load (Rho,
156 0.066; $P=0.44$ for children and Rho, 0.020; $P=0.62$ for adults (Fig. 3C and 3D).

157 **Comparison of URT SARS-CoV-2 RNA load in symptomatic vs. asymptomatic** 158 **children and adults**

159 Children with COVID-19 symptoms displayed slightly higher SARS-CoV-2 RNA load
160 than their asymptomatic counterparts (Fig. 5A), although statistical significance was not
161 reached ($P=0.61$). In adults, median estimated SARS-CoV-2 RNA load was
162 significantly higher in symptomatic than asymptomatic subjects ($P=<0.001$) (Fig. 5B),
163 nevertheless, it was comparable ($P=0.61$) when patients sampled within 48 h after
164 symptoms onset were excluded from the analysis (Supplementary Fig. 1).

165 **Inference of the percentage of children and adults presumably shedding infectious** 166 **virions**

167 We previously reported that SARS-CoV-2 could not be cultured from NP specimens
168 returning $C_T > 25$ ($< 5.9 \log_{10}$ copies/ml) by the TaqPath COVID-19 RT-PCR [16]. We

169 investigated the distribution of specimens yielding $C_T < 25$ across children and adults.
170 The data are shown in Supplementary Fig. 2. Overall, the percentage of NP specimens
171 returning SARS-CoV-2 N RT-PCR C_T s below the abovementioned threshold was
172 similar for symptomatic children and adults ($P=0.28$) and was also comparable between
173 asymptomatic children and adults ($P=0.87$). Among children, that percentage appeared
174 higher for those aged under 3 years. For most age groups the percentage was higher in
175 symptomatic than in asymptomatic subjects, although these differences did not reach
176 statistical significance.

177 **Assessment of the cellularity of NP specimens collected from pediatric and adult** 178 **participants**

179 To assess the quality of NP specimens collected from children and adults regarding
180 cellularity, we randomly selected 30 samples from each population group ($n=60$) that
181 were matched in SARS-CoV-2 RNA load (median 5.70 \log_{10} copies/ml; range 3.5-11.6
182 \log_{10} copies/mL in specimens from children; median, 6.60 \log_{10} copies/ml; range, 2.2-
183 10.9 \log_{10} copies/ml in specimens from adults; $P=0.99$). These specimens were assayed
184 with an in-house designed RT-PCR amplifying the housekeeping GUSB gene. The C_T
185 of NP samples obtained from children and adults did not differ significantly (median
186 C_T , 28.1; range, 24.8-32.7; and median C_T , 29.0; range, 25.2-31.7, respectively, $P=0.3$),
187 suggesting that SARS-CoV-2 RNA loads measured in the two population groups were
188 not biased by differences in cellularity across NP specimens.

189 **DISCUSSION**

190 To our knowledge, this is one of the largest studies to date investigating how children
191 and adults (either asymptomatic or presenting with mild COVID-19 at time of
192 sampling) compare regarding URT SARS-CoV-2 RNA shedding. Several major

193 findings arose from the current study. First, overall, there was no significant difference
194 in initial URT SARS-CoV-2 RNA load between COVID-19 pediatric and adult patients.
195 Furthermore, the percentage of NP specimens potentially yielding infectious virions (C_T
196 <25), as previously estimated [16], was similar across children and adults. Interestingly,
197 a subanalysis categorizing patients by time to specimen collection since symptoms onset
198 revealed that SARS-CoV-2 RNA loads in children and adults were comparable at early
199 times (within 48 h), when peak levels are known to be reached [19], but were
200 significantly lower in children at later times, suggesting a faster URT SARS-CoV-2
201 RNA clearance rate in children. In accordance with our data, Baggio et al [10] found
202 similar estimated SARS-CoV-2 loads in children and adults sampled within the first 5
203 days after onset of symptoms. Likewise, Heald-Sargent et al. [9] found that preschool-
204 and school-aged children sampled within one week after symptoms onset display
205 similar SARS-CoV-2 RNA loads to their adult counterparts. In contrast, a slightly lower
206 SARS-CoV-2 RNA load in children than adults was reported in a German study [8];
207 however, information on symptom onset was not provided [8].

208 Second, pairwise comparison analyses revealed no significant differences in SARS-
209 CoV-2 RNA load across age groups, in either symptomatic children or adults; in
210 children, a similar conclusion can be derived from the study by Kociolek and colleagues
211 [12]. In contrast, age-related differences in SARS-CoV-2 RNA load have been reported
212 previously in children [9,10]; specifically, young children (<5 years old) had
213 significantly lower median SARS-CoV-2 RT-PCR C_T values than older children and
214 adults. Further studies involving larger cohorts are warranted to explain this apparent
215 discrepancy.

216 Third, SARS-CoV-2 transmission to susceptible individuals from asymptomatic
217 infected adults has been documented and postulated to facilitate virus dissemination in

218 the community [20-22]. Here, we found no difference either in SARS-CoV-2 RNA
219 loads or the percentage of NP specimens presumably yielding infectious virus between
220 asymptomatic adults and children, irrespective of the age group considered, suggesting
221 that asymptomatic children may contribute to virus spreading to the same extent as
222 adults seemingly do.

223 Fourth, previous studies reported an overlapping initial SARS-CoV-2 RNA load
224 distribution in symptomatic and asymptomatic adults, regardless of age and baseline
225 medical condition [23,24]. Here, contrarily, we observed higher viral loads in
226 symptomatic than in asymptomatic adults; however, this difference disappeared when
227 excluding patients sampled very early after onset of symptoms from the analyses. While
228 the kinetics of SARS-CoV-2 RNA load in URT has been clearly established in
229 symptomatic individuals, with viral load peaking within 48 h after symptoms onset, it
230 remains to be precisely characterized in asymptomatic subjects; as a result, between-
231 group differences in results in the latter subset likely depend upon the time window of
232 specimen collection. Regarding children, we found similar SARS-CoV-2 loads in
233 symptomatic and asymptomatic individuals, although a subtle trend towards higher viral
234 loads was seen in the former. Our data concur with those of Hurst and et al.²⁵, but are in
235 contradiction to those of Kociolek et al.¹² which clearly pointed to lower SARS-CoV-2
236 RNA loads in asymptomatic children than in those with mild to moderate COVID-19.
237 In this regard, it must be stressed that in our study asymptomatic individuals were tested
238 relatively soon after exposure, whereas in Kociolek's the authors admit a potential
239 population bias towards lower SARS-CoV-2 loads due to an excessive number of
240 remote infections detected via screening programs (i.e. hospital pre-admission).

241 Like the majority of commercially-available SARS-CoV-2 RT-PCRs, the RT-PCR
242 assays used in the current study do not co-amplify a housekeeping gene, thus precluding

243 assessment of sample cellularity. Given the widely varying quality of NP specimens
244 [26] which impacts significantly on estimated SARS-CoV-2 RNA loads [26], we
245 compared a randomly selected set of NP specimens from children and adults for their
246 cellular content using a housekeeping-gene RT-PCR set in parallel. We found
247 overlapping CTs in samples from both subject groups, making it unlikely that
248 differences in cellularity had a major impact on our results. However, only a small
249 number of NP specimens were screened for their cellular content.

250 The current study has several limitations. First, clinical outcome of asymptomatic
251 individuals, which may be determined by peak viral load, could not be ascertained in a
252 large number of participants. Second, only initial SARS-CoV-2 loads were taken into
253 consideration in the analyses, so that we could not have captured the true virus
254 replication rate on an individual basis. Third, no attempt was made to subcategorize
255 individuals according to their baseline medical condition.

256 In summary, we conclude that SARS-CoV-2 RNA loads in non-hospitalized or
257 asymptomatic COVID-19 children of all ages were comparable to those estimated in
258 adults. Our findings indicate that children may spread SARS-CoV-2 in the general
259 population at the same level as adults.

260 **ACKNOWLEDGMENTS**

261 We thank all personnel working at Health Department Clínico-Malvarrosa for their
262 unwavering commitment in the fight against COVID-19. Eliseo Albert holds a Río
263 Hortega research contract from the Carlos III Health Institute (Ref. CM18/00221).

264 **FINANCIAL SUPPORT**

265 This work received no public or private funds.

266 **CONFLICTS OF INTEREST**

267 The authors declare no conflicts of interest.

268 **AUTHOR CONTRIBUTIONS**

269 RC, FB, EA, IT, DS, CP and JC: Methodology and data collection. RC, FB: Formal
270 analysis. RC, FB, CM-C and DN: Conceptualization and validation of data. S C-S, AB-
271 F, MILC, JRB-M and CM-C were physicians in charge of children. DN: writing the
272 original draft. All authors reviewed and approved the original draft.

273 **REFERENCES**

274 1. Viner RM, Mytton OT, Bonell C, Melendez-Torres GJ, Ward J, et al. Susceptibility
275 to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A
276 Systematic Review and Meta-analysis. *JAMA Pediatr* 2021;175:143-156.

277 2. Wölfel R., Corman V.M., Guggemos W., Seilmaier M., Zange S., Müller M.A.
278 Virological assessment of hospitalized patients with COVID-2019. *Nature*
279 2020;581:465–469.

280 3. Huang CG, Lee KM, Hsiao MJ, Yang SL, Huang PN, Gong YN. Culture-based virus
281 isolation to evaluate potential infectivity of clinical specimens tested for COVID-19. *J*
282 *Clin Microbiol* 2020;58 e01068-20.

283 4. Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L. Predicting infectious
284 severe acute respiratory syndrome coronavirus 2 from diagnostic samples. *Clin Infect*
285 *Dis* 2020:ciaa638.

286 5. L'Huillier AG, Torriani G, Pigny F, Kaiser L, Eckerle I. Culture-competent SARS-
287 CoV-2 in nasopharynx of symptomatic neonates, children, and adolescents. *Emerg*
288 *Infect Dis* 2020;26:26.

- 289 6. Marks M, Millat-Martinez P, Ouchi D, Roberts CH, Alemany A, Corbacho-Monné
290 M, et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study.
291 *Lancet Infect Dis* 2021;S1473-3099(20)30985-3.
- 292 7. Colson P, Tissot-Dupont H, Morand A, Boschi C, Ninove L, Esteves-Vieira V, et al.
293 Children account for a small proportion of diagnoses of SARS-CoV-2 infection and do
294 not exhibit greater viral loads than adults. *Eur J Clin Microbiol Infect Dis*
295 2020;39:1983-1987.
- 296 8. Jones TC, Mühlemann B, Veith T, Biele G, Zuchowski M, Hoffmann J, et al. An
297 analysis of SARS-CoV-2 viral load by patient age. *medRxiv*
298 2020:20125484:2020.06.08.20125484.
- 299 9. Heald-Sargent T, Muller WJ, Zheng X, Rippe J, Patel AB, Kociolek LK. Age-related
300 differences in nasopharyngeal severe acute respiratory syndrome coronavirus 2 (SARS-
301 CoV-2) levels in patients with mild to moderate coronavirus disease 2019 (COVID-19).
302 *JAMA Pediatr* 2020; 174:902.
- 303 10. L'Huillier AG, Baggio S, Eckerle I. Viral Loads of SARS-CoV-2 in Young
304 Children. *JAMA Pediatr* 2021; Feb 1. doi: 10.1001/jamapediatrics.2020.5548.
- 305 11. Baggio S., L'Huillier AG, Yerly S, Bellon M, Wagner N, Rohr M. SARS-CoV-2
306 viral load in the upper respiratory tract of children and adults with early acute COVID-
307 19. *Clin Infect Dis* 2020:ciaa1157.
- 308 12. Kociolek LK, Muller WJ, Yee R, Dien Bard J, Brown CA, Revell PA, et al.
309 Comparison of Upper Respiratory Viral Load Distributions in Asymptomatic and
310 Symptomatic Children Diagnosed with SARS-CoV-2 Infection in Pediatric Hospital
311 Testing Programs. *J Clin Microbiol* 2020;59:e02593-20.

- 312 13. Han MS, Choi EH, Chang SH, Jin BL, Lee EJ, Kim BN, et al. Clinical
313 Characteristics and Viral RNA Detection in Children With Coronavirus Disease 2019 in
314 the Republic of Korea. *JAMA Pediatr* 2021;175:73-80.
- 315 14. Kam KQ, Thoon KC, Maiwald M, Chong CY, Soong HY, Loo LH, et al. SARS-
316 CoV-2 viral RNA load dynamics in the nasopharynx of infected children. *Epidemiol
317 Infect* 2021;11;149:e18A.
- 318 15. Estrategia de detección precoz, vigilancia y control de COVID-19.
319 [https://www.mschs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/docu](https://www.mschs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/COVID19_Estrategia_vigilancia_y_control_e_indicadores.pdf)
320 [mentos/COVID19 Estrategia vigilancia y control e indicadores.pdf](https://www.mschs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/COVID19_Estrategia_vigilancia_y_control_e_indicadores.pdf). November 11
321 [2020](https://www.mschs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/COVID19_Estrategia_vigilancia_y_control_e_indicadores.pdf).
- 322 16. Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernández-Fuentes MÁ, et al.
323 Field evaluation of a rapid antigen test (Panbio COVID-19 Ag Rapid Test Device) for
324 COVID-19 diagnosis in primary healthcare centres. *Clin Microbiol Infect* 2020;S1198-
325 743X(20)30697-2.
- 326 17. Torres I, Poujois S, Albert E, Colomina J, Navarro D. Evaluation of a rapid antigen
327 test (Panbio COVID-19 Ag rapid test device) for SARS-CoV-2 detection in
328 asymptomatic close contacts of COVID-19 patients. *Clin Microbiol Infect* 2021;S1198-
329 743X(20)30782-5.
- 330 18. Albert E, Ferrer B, Torres I, Serrano A, Alcaraz MJ, Buesa J, et al. Amplification of
331 human beta-glucuronidase gene for appraising the accuracy of negative SARS-CoV-2
332 RT-PCR results in upper respiratory tract specimens. *J Med Virol* 2020 Jun
333 2:10.1002/jmv.26112.

- 334 19. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-
335 CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and
336 infectiousness: a systematic review and meta-analysis. *Lancet Microbe* 2021;2:e13-e22.
- 337 20. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral
338 Load in Upper Respiratory Specimens of Infected Patients. *N Engl J Med*
339 2020;382:1177-1179.
- 340 21. Huff HV, Singh A. Asymptomatic transmission during the COVID-19 pandemic
341 and implications for public health strategies. *Clin Infect Dis* 2020:ciaa654
- 342 22. Johansson MA, Quandelacy TM, Kada S, Prasad PV, Steele M, Brooks JT, et al.
343 SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. *JAMA Netw*
344 *Open* 2021;4:e2035057.
- 345 23. Lee S, Kim T, Lee E, Lee C, Kim H, Rhee H, et al. Clinical Course and Molecular
346 Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2
347 Infection in a Community Treatment Center in the Republic of Korea. *JAMA Intern*
348 *Med* 2020 ;180:1-6.
- 349 24. Ra SH, Lim JS, Kim GU, Kim MJ, Jung J, Kim SH. Upper respiratory viral load in
350 asymptomatic individuals and mildly symptomatic patients with SARS-CoV-2
351 infection. *Thorax* 2021;76:61-63.
- 352 25. Hurst JH, Heston SM, Chambers HN, Cunningham HM, Price MJ, Suarez L, et al.
353 SARS-CoV-2 Infections Among Children in the Biospecimens from Respiratory Virus-
354 Exposed Kids (BRAVE Kids) Study. *Clin Infect Dis* 2020:ciaa1693

355 26. Albert E, Bracho MA, Serrano A, Ferrer B, González-Candelas F, Navarro D.
356 Assessing the potential association between SARS-CoV-2 RNA load in the respiratory
357 tract and COVID-19 mortality. J Med Virol 2020; Nov 2. doi: 10.1002/jmv.26644.

358 .

359 **FIGURE LEGENDS**

360 **Figure 1.** Overall estimated initial SARS-CoV-2 RNA loads in nasopharyngeal
361 specimens from children and adults with COVID-19 (A) and those found across
362 different pediatric and adult ages (B). Medians are indicated by midlines, the top and
363 bottom edges of boxes represent the interquartile range (IQR). Whiskers indicate the
364 upper and lower values. The number of patients in each group as well as *P* values for
365 comparisons between groups (median SARS-CoV-2 RNA levels) are shown.

366 **Figure 2.** Estimated initial SARS-CoV-2 RNA loads in nasopharyngeal specimens from
367 children and adults with COVID-19 according to the time of sampling after symptoms
368 onset. Medians are indicated by midlines, the top and bottom edges of boxes represent
369 the interquartile range (IQR). Whiskers indicate the upper and lower values. The
370 number of patients in each group as well as *P* values for comparisons between groups
371 (median SARS-CoV-2 RNA levels) are shown.

372 **Figure 3.** Correlation between estimated initial SARS-CoV-2 RNA load in
373 nasopharyngeal specimens from adults (A) and children (B) with COVID-19, and from
374 asymptomatic adults (C) and children (D) and age of participants.

375 **Figure 4.** Overall estimated initial SARS-CoV-2 RNA loads in nasopharyngeal
376 specimens from asymptomatic children and adults with COVID-19 (A) and those found
377 across different pediatric and adult ages (B). Medians are indicated by midlines, the top
378 and bottom edges of boxes represent the interquartile range (IQR). Whiskers indicate

379 the upper and lower values. The number of patients in each group as well as *P* values
380 for comparisons between groups (median SARS-CoV-2 RNA levels) are shown.

381 **Figure 5.** Comparison of estimated initial SARS-CoV-2 RNA loads in nasopharyngeal
382 specimens from children (A) and adults (B) either asymptomatic or presenting with
383 COVID-19. Medians are indicated by midlines, the top and bottom edges of boxes
384 represent the interquartile range (IQR). Whiskers indicate the upper and lower values.
385 The number of patients in each group as well as *P* values for comparisons between
386 groups (median SARS-CoV-2 RNA levels) are shown.

387 **Supplementary Figure 1.** Comparison of estimated initial SARS-CoV-2 RNA loads in
388 nasopharyngeal specimens from adults either asymptomatic or presenting with COVID-
389 19 within 48 h after onset of symptoms. Medians are indicated by midlines, the top and
390 bottom edges of boxes represent the interquartile range (IQR). Whiskers indicate the
391 upper and lower values. The number of patients in each group as well as *P* values for
392 comparisons between groups (median SARS-CoV-2 RNA levels) are shown.

393 **Supplementary Figure 2.** Percentage of nasopharyngeal specimens from children or
394 adults across different age groups returning RT-PCR CTs <25.

395

Figure 1





Figure 2




Figure 3







Figure 4





Figure 5

A

